Juno Therapeutics, Inc. (JUNO) Given “Buy” Rating at Cowen and Company

Cowen and Company reissued their buy rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research note published on Friday.

A number of other research firms have also recently commented on JUNO. Wedbush upgraded Juno Therapeutics from a neutral rating to an outperform rating and set a $42.00 price target for the company in a report on Tuesday, August 29th. Wells Fargo & Company reiterated an outperform rating and set a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial, Inc. upgraded Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 price target for the company in a report on Tuesday, August 29th. Standpoint Research reiterated a reduce rating on shares of Juno Therapeutics in a report on Thursday, August 31st. Finally, Goldman Sachs Group, Inc. (The) reiterated a neutral rating and set a $44.00 price target on shares of Juno Therapeutics in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $44.20.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $1.43 during midday trading on Friday, hitting $58.48. The stock had a trading volume of 5,482,719 shares, compared to its average volume of 2,209,417. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 5.08. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter last year, the company posted ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% on a year-over-year basis. sell-side analysts forecast that Juno Therapeutics will post -3.62 EPS for the current fiscal year.

WARNING: “Juno Therapeutics, Inc. (JUNO) Given “Buy” Rating at Cowen and Company” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/06/juno-therapeutics-inc-juno-given-buy-rating-at-cowen-and-company.html.

In other news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,670 shares of company stock valued at $3,917,857. Corporate insiders own 15.26% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JUNO. Bank of New York Mellon Corp raised its position in shares of Juno Therapeutics by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 262,801 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 7,165 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Juno Therapeutics by 76.4% in the first quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock valued at $663,000 after buying an additional 12,947 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in shares of Juno Therapeutics by 88.6% in the first quarter. Parametric Portfolio Associates LLC now owns 39,826 shares of the biopharmaceutical company’s stock valued at $884,000 after buying an additional 18,713 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Juno Therapeutics by 2,185.8% in the first quarter. JPMorgan Chase & Co. now owns 62,746 shares of the biopharmaceutical company’s stock valued at $1,393,000 after buying an additional 60,001 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock valued at $1,428,000 after buying an additional 3,531 shares in the last quarter. Institutional investors own 67.18% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply